middle.news
Race Oncology Secures 20-Year Patent Edge with Bisantrene Breakthrough
9:15am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
Race Oncology Secures 20-Year Patent Edge with Bisantrene Breakthrough
9:15am on Friday 31st of October, 2025 AEDT
Key Points
Three new patents filed on active (E,E)-bisantrene isomer
Phase 1 trial of RC220 progresses with two patients treated safely
Expansion of clinical trial sites in Hong Kong and South Korea
Cash reserves at $11.27 million with additional funds from option conversions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE